/PRNewswire/ -- B. Braun Medical Inc. (B. Braun), a leader in smart infusion therapy and pain management, announced that the U.S. Food and Drug Administration (FDA) has approved Piperacillin and Tazobactam, one of the most utilized injectable antibiotics in the U.S.,

/PRNewswire/ -- B. Braun Medical Inc.（B. Braun），智能输液治疗和疼痛管理领域的领导者，宣布美国食品药品监督管理局（FDA）已批准哌拉西林和他唑巴坦，这是美国最常用的注射用抗生素之一。

for use in the Company's DUPLEX

供公司DUPLEX使用

Drug Delivery System and will begin moving toward a full launch.

药物输送系统，并将开始朝着全面上市迈进。

Piperacillin and Tazobactam in the DUPLEX Drug Delivery System is a ready-to-activate, two-compartment container that keeps pre-measured medication and diluent separate until the provider is ready to administer at the bedside by simply folding, squeezing and shaking to reconstitute. This system reduces overall process time by nearly four minutes per dose and shows substantial labor time savings compared to both the Baxter Mini-Bag Plus Container System and traditional compounding, offering healthcare professionals a new and efficient way to administer this critical antibiotic combination..

派珀拉西林和他唑巴坦在DUPLEX药物输送系统中是一种即用型、双腔容器，可以将预先测量好的药物和稀释剂分开存放，直到医护人员准备在床边给药时，只需折叠、挤压和摇晃即可混合。该系统每次剂量可减少近四分钟的整体操作时间，与Baxter Mini-Bag Plus容器系统以及传统配药相比，显示出显著的劳动时间节省，为医疗专业人员提供了一种高效的新方式来使用这种关键的抗生素组合。

DUPLEX is also designed to reduce contamination risks and medication errors. The closed-system design helps protect potency and ensures the diluent cannot be delivered without the drug. Furthermore, DUPLEX decreases the likelihood of medication errors by 54% compared to traditional compounding methods based on fewer process steps..

DUPLEX还旨在减少污染风险和药物错误。封闭系统设计有助于保护药效，并确保稀释剂不能在没有药物的情况下被输送。此外，与传统的配药方法相比，DUPLEX通过减少操作步骤，将药物错误的可能性降低了54%。

DUPLEX requires no thawing and can be stored at room temperature or in automated dispensing cabinets.

DUPLEX无需解冻，可以存放在室温或自动分配柜中。

'We are excited to introduce Piperacillin and Tazobactam in our innovative DUPLEX Drug Delivery System, designed to save time, labor, and space, and reduce waste,' said

“我们很高兴在我们的创新DUPLEX药物输送系统中引入哌拉西林和他唑巴坦，该系统旨在节省时间、人力和空间，并减少浪费，”

Jeremy Greene

杰里米·格林

, Senior Director of Marketing at B. Braun Medical. 'Enhancing efficiency for nurses and pharmacists aligns with our commitment to providers and the patients they serve. And, the DUPLEX Container is not made with DEHP or PVC, further protecting patients and the environment.'

，B. Braun Medical的市场高级总监。“提高护士和药剂师的效率符合我们对供应商及其服务患者的承诺。此外，DUPLEX容器不含DEHP或PVC，进一步保护患者和环境。”

Piperacillin and Tazobactam in the DUPLEX Drug Delivery System will mark the second DUPLEX Drug launch in 2025 (in addition to Cefazolin 3g) and is one of many planned injectable drugs B. Braun will launch in the U.S. in the next several years to expand its portfolio and help meet the needs of patients for medications in high demand. .

Piperacillin 和 Tazobactam 在 DUPLEX 药物输送系统中将成为2025年第二个推出的DUPLEX药物（仅次于头孢唑林3g），并且是B. Braun计划在未来几年内在美国推出的众多注射药物之一，以扩大其产品组合，并帮助满足患者对高需求药物的需求。

About B. Braun

关于B. Braun

B. Braun Medical Inc. (B. Braun) is a leader in smart infusion therapy and safe and effective pharmacy products, patient and provider safety, and sustainable health solutions. Our purpose is to help providers constantly improve patient satisfaction and outcomes. With products and services created to help healthcare professionals focus on what matters most—their patients—we're uniquely positioned to help health systems succeed now and in the future.

B. Braun Medical Inc.（B. Braun）是智能输液治疗、安全有效的药房产品、患者和供应商安全以及可持续健康解决方案的领导者。我们的宗旨是帮助医疗供应商不断提高患者的满意度和治疗效果。通过为医疗专业人员提供专注于最重要事情——他们的患者——的产品和服务，我们能够独特地帮助医疗系统现在和未来取得成功。